Edgewise Therapeutics Talks Phase III Becker Readout, EDG-7500 HCM Data Due in Q2 at Conference [Yahoo! Finance]
Edgewise Therapeutics, Inc. (EWTX)
Company Research
Source: Yahoo! Finance
Executives from Edgewise Therapeutics (NASDAQ:EWTX) highlighted recent clinical updates and upcoming milestones across the company's neuromuscular and cardiovascular pipeline during a discussion hosted by Leerink Partners' Joseph Schwartz, with CEO Kevin Koch and COO Behrad Derakhshan providing commentary. Becker muscular dystrophy: posters and a Phase III timeline Koch said the company recently presented two posters at the Muscular Dystrophy Association meeting. One poster included early observations from the GRAND CANYON study that referenced cardiovascular-related endpoints. Koch said that among patients with a low ejection fraction, the company observed increases in ejection fraction, and discussed NT-proBNP as a heart failure-associated biomarker. He added that patients who were normal did not show changes in NT-proBNP, while patients who were not on sevasemten showed increases in that biomarker. ? Broadcom's AI Momentum Could Be Far From Over Analysts Think There's Stil
Show less
Read more
Impact Snapshot
Event Time:
EWTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EWTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EWTX alerts
High impacting Edgewise Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
EWTX
News
- Why Edgewise Therapeutics Stock Topped the Market on Tuesday [Yahoo! Finance]Yahoo! Finance
- Edgewise Therapeutics (EWTX) had its price target raised by JPMorgan Chase & Co. from $34.00 to $45.00. They now have an "overweight" rating on the stock.MarketBeat
- Edgewise Therapeutics (EWTX) had its "outperform" rating reaffirmed by Wedbush. They now have a $32.00 price target on the stock.MarketBeat
- Why Edgewise Therapeutics (EWTX) Is Up 6.4% After Long-Term Sevasemten Becker Data - And What's Next [Yahoo! Finance]Yahoo! Finance
- Edgewise Therapeutics (EWTX) was given a new $46.00 price target by Raymond James Financial, Inc..MarketBeat
EWTX
Earnings
- 2/26/26 - Miss
EWTX
Sec Filings
- 2/26/26 - Form 10-K
- 2/26/26 - Form 8-K
- 2/17/26 - Form SCHEDULE
- EWTX's page on the SEC website